P–P and Q–Q plots for assessing normality of residuals. by Kazuhiro Suzuki (160528)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Changes in reported rate of AEFIs in the pre-LAW and post-LAW period(/10000). by Chao Zhang (51048)

Subjects:

Data. by Chao Zhang (51048)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Comparing admission rate of each ward before and during COVID-19 outbreak. by Mahsa Motiei (18275525)

Subjects:

Comparing diagnosis based on ICD-10 criteria in patients before and after COVID-19 outbreak. by Mahsa Motiei (18275525)

Subjects:

Demographic information of participating emergency medicine physicians. by Leigh V. Evans (19753987)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

CONSORT flow diagram depicting participant flow through the trial. by Leigh V. Evans (19753987)

Subjects:

Characteristics of the participants. by Kazuhiro Suzuki (160528)

Subjects:

Comparison of GHQ-12 total scores pre- and post- guideline change in the mask-wearing behavior. by Kazuhiro Suzuki (160528)

Subjects:

Comparison of HRV and STAI between intervention and control at Pre-CRI:SIS and Post-CRI-SIS shifts from linear mixed model for repeated measures. by Leigh V. Evans (19753987)

Subjects:

Characteristics of AEFIs with JEV-L vaccine in the pre-LAW and post-LAW period. by Chao Zhang (51048)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Comparing demographic and clinical characteristics of patients before and COVID-19 outbreak. by Mahsa Motiei (18275525)

Subjects:

Reporting rate of AEFI of JEV-L in Huzhou, Zhejiang province, 2014–2023 (/10,000). by Chao Zhang (51048)

Subjects:

Analysis sample data. by Kazuhiro Suzuki (160528)

Subjects: